An interventional study of Apixaban 2.5 MG in Cirrhosis, Splenectomy and Portal Vein Thrombosis, sponsored by Northern Jiangsu People's Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-31.
Sponsored by Northern Jiangsu People's Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Hypertension, Portal by Northern Jiangsu People's Hospital — 8 open to participants now, 8 under way, none of them phase 3. Hypertension, Portal · Northern Jiangsu People's Hospital.
Among the 12 studies in Hypertension, Portal by Northern Jiangsu People's Hospital, this one is one of 7 that started in 2026, is one of 5 with no phase, and was the 5th registered.
376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.
Browse Hypertension, Portal studies →8 of the 12 studies in Hypertension, Portal by Northern Jiangsu People's Hospital are open now, in 1 country. Recruiting first, the newest first:
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18+
Northern Jiangsu People's Hospital · Sites in China
Ages 18–80
Northern Jiangsu People's Hospital
Ages 18–80
By country, each count listing its studies:
Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 60 across 232 interventional studies indexed under Hypertension, Portal.
Median enrollment 20 across the 6 interventional studies, 30 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northern Jiangsu People's Hospital is the lead sponsor of 61 studies on the registry; 31 are open to participants now.
3 of the studies in Hypertension, Portal by Northern Jiangsu People's Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07462091Northern Jiangsu People's HospitalVagus Nerve-guided Laparoscopic Splenectomy and Azygoportal Disconnection | 2027-03-31 |
| NCT07461532Northern Jiangsu People's HospitalEfficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD | 2027-09-30 |
| NCT07461545Northern Jiangsu People's HospitalEfficacy of Apixaban in the Treatment of Portal Vein Thrombosis Occurring More Than One Year After LS | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies in Hypertension, Portal by Northern Jiangsu People's Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
If portal vein thrombosis occurs more than one year after and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, the efficacy of apixaban in treating portal vein thrombosis will be examined every three months using Doppler ultrasound screening or contrast-enhanced CT scans. If it is effective, the patient will continue to take apixaban.
376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.
This study's planned enrollment of 20 is below the median of 60 across 232 interventional studies indexed under Hypertension, Portal.
Browse Hypertension, Portal studies →Northern Jiangsu People's Hospital is the lead sponsor of 61 studies on the registry; 31 are open to participants now.
Compared within Hypertension, Portal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
If portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.
Drug: Apixaban 2.5 MG
If portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.
Proportion of complete recanalization of portal vein thrombosis
Proportion of complete recanalization of portal vein thrombosis
Time frame: Follow-up of 6 months or greater
Proportion of partial recanalization of portal vein thrombosis
Proportion of partial recanalization of portal vein thrombosis
Time frame: Follow-up of 6 months or greater
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Sep 2027, 17 months later.
Of 57 non-industry interventional studies with no phase under Hypertension, Portal, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 17 months is below that.
Counting every sponsor, half of 61 studies reached it within 41 months; a quarter within 19 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apixaban
Northern Jiangsu People's Hospital